Calmirex, 2.5mg/ml+100 mg/ml 5 pcs.

– hypertonicity and spasm of the transverse striated musculature resulting from organic diseases of the CNS (including lesions of the pyramidal pathways, multiple sclerosis, stroke, myelopathy, encephalomyelitis), the musculoskeletal system (including spondylosis, spondyloarthrosis, cervical and lumbar syndromes of large joints.Including spondylosis, spondyloarthrosis, cervical and lumbar syndromes, arthrosis of large joints);
– Rehabilitation after orthopedic and traumatologic surgeries.
In combination therapy:
– In patients with obliterating vascular diseases (obliterating atherosclerosis, diabetic angiopathy, obliterating thrombangiitis, Raynaud’s disease, diffuse scleroderma);
– In diseases that are caused by a disorder of the innervation of blood vessels (acrocyanosis, intermittent angioneurotic dysbasia).

Composition

Excipients:

methyl parahydroxybenzoate – 0.6 mg,

diethylene glycol monoethyl ether – 0.3 ml,

Hydrochloric acid concentrated – to pH 3.0-4.5,

water d/i – to 1 ml.

.

How to take, the dosage

In adults, the drug is administered daily v/m 100 mg twice a day or intravenously 100 mg once a day.

Interaction

There are no data on drug-drug interactions limiting the use of Calmirex®.

Special Instructions

Influence on the ability to operate vehicles and mechanisms

Contraindications

– Severe myasthenia gravis;
– pregnancy;
– lactation period;
– childhood and adolescence up to 18 years old;
– hypersensitivity to the components of the drug, including lidocaine.
– Caution should be exercised if the drug is used in renal and hepatic insufficiency (dose adjustment is not required).

Side effects

Frequency of side effects: very common (≥1/10), common (≥1/100 to < 1/10), infrequent (≥1/1000 to < 1/100), rare (≥1/10 000 to < 1/1000), very rare (< 1/10 000), frequency unknown (cannot be estimated from available data)

Overdose

Symptoms: ataxia, tonic and clonic convulsions, dyspnea, respiratory arrest.